At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VYNE VYNE Therapeutics Inc.
Trading 11-22 13:33:35 EST
3.10
+0.20
+6.90%
High3.12
Low2.88
Vol37.25K
Open2.88
D1 Closing2.90
Amplitude8.28%
Mkt Cap45.73M
Tradable Cap31.30M
Total Shares14.75M
T/O111.76K
T/O Rate0.37%
Tradable Shares10.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.